APTO News and Press, Aptose Biosciences Inc. From 03/24/21

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Bioscience outfit  Aptose (NASDAQ: APTO ) stock is experiencing a boost this morning, fueled by the company’s newest research updates and earnings report. Source: Shutterstock In a Tuesday afte...

Gainers: Aptose Biosciences (APTO) +65%, Brainstorm Cell Therapeutics (BCLI) +13%, Prothena (PRTA) +12%, Armata Pharmaceuticals (ARMP) +8%, Inventiva (IVA) +8%.Losers: Benitec Biopharma (BNTC) -24%, Second Sight Medical Products (EYES) -1...

Announcing its Q4 2020 results, Aptose Biosciences ([[APTO]] +80.1%) shared the latest updates on its clinical development program for luxeptinib undergoing two Phase 1 a/b studies in R/R acute myeloid leukemia and B-cell Malignancies.For luxeptinib in R/R acute myeloid leukemia, Aptose compl...

Hall of Fame Resort & Entertainment Company (HOFV) +71% after NFT deal.Dolphin Entertainment (DLPN) +66% after NFT deal.Alithya Group (ALYA) +52% on acquisition of R3D ConseilColor Star Technology (CSCW) +41%.Aptose Biosciences (APTO) +39% on Q4 results.Cinedigm C...

Aptose Biosciences Inc. (APTO) Q4 2020 Earnings Conference Call March 23, 2021 05:00 PM ET Company Participants Susan Pietropaolo - SMP Communications, Inc. William Rice - Chairman, President and Chief Executive Officer Rafael Bejar - Senior Vice President and Chief Medical Officer Gregory Ch...

Are These On The Top Of Your Penny Stocks Watch List Right Now? I get it; certain penny stocks are seeing some pressure. However, with as many that are under fire, there are plenty of others that have weathered the latest market volatility like pros. What’s been the differences? ...

Aptose Biosciences (APTO): Q4 GAAP EPS of -$0.17 in-line.Total cash and cash equivalents and investments as of December 31, 2020 were $122.4 million. Based on current operations, Aptose expects that cash on hand and available capital provide the Company with sufficient resources to fund all p...

- Conference call and webcast at 5pm EDT today - - Company announces resignation of CFO Gregory Chow - - Luxeptinib (CG-806) continues dose escalation and evidence of clinical activity - SAN DIEGO and TORONTO, March 23, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences I...

George Melko, Pharm.D. joins as Vice President, Regulatory Affairs Robert Killion, Ph.D. appointed Vice President, CMC SAN DIEGO and TORONTO, March 16, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly dif...

SAN DIEGO and TORONTO, March 02, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will release its financial results for the year and quarter end...